150 related articles for article (PubMed ID: 30417785)
1. Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone.
Kalantzis ED; Scorilas A; Vassilacopoulou D
Curr Pharm Biotechnol; 2018; 19(13):1087-1096. PubMed ID: 30417785
[TBL] [Abstract][Full Text] [Related]
2. Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
Symes JC; Kurin M; Fleshner NE; Medin JA
Mol Cancer Ther; 2008 Sep; 7(9):3018-28. PubMed ID: 18790782
[TBL] [Abstract][Full Text] [Related]
3. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
[TBL] [Abstract][Full Text] [Related]
4. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
Wafa LA; Cheng H; Plaa N; Ghaidi F; Fukumoto T; Fazli L; Gleave ME; Cox ME; Rennie PS
Int J Cancer; 2012 Jun; 130(12):2835-44. PubMed ID: 21780103
[TBL] [Abstract][Full Text] [Related]
5. Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Korbakis D; Fragoulis EG; Scorilas A
Anticancer Drugs; 2013 Mar; 24(3):291-9. PubMed ID: 23328075
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
7. Human L-Dopa decarboxylase interaction with annexin V and expression during apoptosis.
Chalatsa I; Arvanitis N; Arvanitis D; Tsakou AC; Kalantzis ED; Vassiliou AG; Sideris DC; Frakolaki E; Vassilaki N; Vassilacopoulou D
Biochimie; 2020 Oct; 177():78-86. PubMed ID: 32835737
[TBL] [Abstract][Full Text] [Related]
8. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
9. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
10. KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.
Mavridis K; Talieri M; Scorilas A
Biol Chem; 2010 Apr; 391(4):467-74. PubMed ID: 20128692
[TBL] [Abstract][Full Text] [Related]
11. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
12. Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
Shoji K; Teishima J; Hayashi T; Ohara S; Mckeehan WL; Matsubara A
Oncol Rep; 2014 Jul; 32(1):65-70. PubMed ID: 24839986
[TBL] [Abstract][Full Text] [Related]
13. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
[TBL] [Abstract][Full Text] [Related]
14. L-Dopa decarboxylase expression profile in human cancer cells.
Chalatsa I; Nikolouzou E; Fragoulis EG; Vassilacopoulou D
Mol Biol Rep; 2011 Feb; 38(2):1005-11. PubMed ID: 20535562
[TBL] [Abstract][Full Text] [Related]
15. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
16. The U937 macrophage cell line expresses enzymatically active L-Dopa decarboxylase.
Kokkinou I; Fragoulis EG; Vassilacopoulou D
J Neuroimmunol; 2009 Nov; 216(1-2):51-8. PubMed ID: 19800137
[TBL] [Abstract][Full Text] [Related]
17. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Thomadaki H; Mavridis K; Talieri M; Scorilas A
Thromb Haemost; 2009 Feb; 101(2):373-80. PubMed ID: 19190824
[TBL] [Abstract][Full Text] [Related]
18. Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes.
Kokkinou I; Nikolouzou E; Hatzimanolis A; Fragoulis EG; Vassilacopoulou D
Blood Cells Mol Dis; 2009; 42(1):92-8. PubMed ID: 19041269
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
Koceva-Chyła A; Jedrzejczak M; Skierski J; Kania K; Jóźwiak Z
Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
[TBL] [Abstract][Full Text] [Related]
20. Molecular characteristic and physiological role of DOPA-decarboxylase.
Guenter J; Lenartowski R
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1424-1440. PubMed ID: 28100850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
